TP53 and B-cell chronic lymphocytic leukemia: Mutations in CLL drivers associated with aggressive clinical course such as TP53, BIRC3, RPS15, and NFKBIE [4, 13–15] were mostly detected within the AD/SD groups (Fig. 2).